Privacy Policy
Signals Blog

Contributors

Categories

Cell Therapy Deal Review: January

Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno...

Series: Spotlight on Cell Therapy

Cell therapy is not a new idea. Bone marrow transplantation—the first ever cell therapy—has been around since the 1950s. Over half a century of research has brought important advancements, yet this technology has struggled to make it to prime time. Understandably,...

Right Turn: Moving from STEM to STEAM

Are you a glass half full or half empty kind of person? If you’re the former, and you think more is better, being inclusive and diverse benefits humanity, and that children are our future, then this should be in your sweet spot (meaning “an optimum point or...

Regenerating a broken heart

Samantha is a PhD student in the Chemical Engineering and Applied Chemistry department at the University of Toronto. She has previously investigated regeneration in a non-mammalian gecko model during an MSc program, and now currently combines stem cell biology and...

The enabling technology of polymer design

Another in the series: “What drives research in the field of biomaterials?” “What makes Canada cool?” asks Dan Taekema of The Toronto Star, and among the handful of influential figures that he writes about is the “rock star” researcher, Professor Molly Shoichet. I was...

RoosterBio: Helping researchers scale up cells for patient delivery

John Farrell is a science and technology blogger for Forbes online. John was invited to cover proceedings at the 2015 Till & McCulloch Meetings and this is his third and final report. This blog also appears on Forbes and is reprinted here with permission. One of...

Right Turn: Regenerative medicine debuts on The Late Show

Does it seem like regenerative medicine is having its moment in the sun? Last week, the news that GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies, with $20 million...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!